Skip to main content
Top
Published in: CEN Case Reports 1/2018

Open Access 01-05-2018 | Case Report

A case of ABO-incompatible blood transfusion treated by plasma exchange therapy and continuous hemodiafiltration

Authors: Akio Namikawa, Yuko Shibuya, Haruki Ouchi, Hiroko Takahashi, Yoshitaka Furuto

Published in: CEN Case Reports | Issue 1/2018

Login to get access

Abstract

ABO-incompatible blood transfusion is potentially a life-threatening event. A 74-year-old type O Rh-positive male was accidentally transfused with 280 mL type B Rh-positive red blood cells during open right hemicolectomy, causing ABO-incompatible blood transfusion. Immediately after the transfusion, the patient experienced a hypotension episode followed by acute hemolytic reaction, disseminated intravascular coagulation and acute kidney injury. Plasma exchange therapy was performed to remove anti-B antibody and free hemoglobin because they caused acute hemolytic reaction, disseminated intravascular coagulation, and acute kidney injury. Free hemoglobin levels decreased from 13 to 2 mg/dL for 2 h. Continuous hemodiafiltration was used to stabilize hemodynamics. The patient was successfully treated for acute hemolytic reaction, disseminated intravascular coagulation, and acute kidney injury. Plasma exchange therapy and continuous hemodiafiltration are likely to be effective treatments for ABO-incompatible blood transfusion, and further studies are required to assess this effectiveness in future.
Literature
1.
go back to reference Janatpour KA, Kalman ND, Jensen HM, Holland PV. Clinical outcomes of ABO-incompatible RBC transfusions. Am J Clin Pathol. 2008;129:276–81.CrossRefPubMed Janatpour KA, Kalman ND, Jensen HM, Holland PV. Clinical outcomes of ABO-incompatible RBC transfusions. Am J Clin Pathol. 2008;129:276–81.CrossRefPubMed
2.
go back to reference Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York state: an analysis of 10 years’ experience. Transfusion. 2000;40:1207–13.CrossRefPubMed Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York state: an analysis of 10 years’ experience. Transfusion. 2000;40:1207–13.CrossRefPubMed
3.
go back to reference Klein HG, Anstee DJ. Mollison.’s blood transfusion in clinical medicine. 12th ed. Wiley: Blackwell; 2014. Klein HG, Anstee DJ. Mollison.’s blood transfusion in clinical medicine. 12th ed. Wiley: Blackwell; 2014.
4.
go back to reference Butler J, Parker D, Pillai R, Shale DJ, Rocker GM. Systemic release of neutrophil elastase and tumour necrosis factor alpha following ABO incompatible blood transfusion. Br J Haematol. 1991;79:525–6.CrossRefPubMed Butler J, Parker D, Pillai R, Shale DJ, Rocker GM. Systemic release of neutrophil elastase and tumour necrosis factor alpha following ABO incompatible blood transfusion. Br J Haematol. 1991;79:525–6.CrossRefPubMed
5.
go back to reference Davenport RD, Polak TJ, Kunkel SL. White cell-associated procoagulant activity induced by ABO incompatibility. Transfusion. 1994;34:943–9.CrossRefPubMed Davenport RD, Polak TJ, Kunkel SL. White cell-associated procoagulant activity induced by ABO incompatibility. Transfusion. 1994;34:943–9.CrossRefPubMed
6.
go back to reference Wagener FA, Eggert A, Boerman OC, Oyen WJ, Verhofstad A, Abraham NG, et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood. 2001;98:1802–11.CrossRefPubMed Wagener FA, Eggert A, Boerman OC, Oyen WJ, Verhofstad A, Abraham NG, et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood. 2001;98:1802–11.CrossRefPubMed
7.
go back to reference Davenport RD, Strieter RM, Standiford TJ, Kunkel SL. Interleukin-8 production in red blood cell incompatibility. Blood. 1990;76:2439–42.PubMed Davenport RD, Strieter RM, Standiford TJ, Kunkel SL. Interleukin-8 production in red blood cell incompatibility. Blood. 1990;76:2439–42.PubMed
8.
go back to reference Davenport RD, Strieter RM, Kunkel SL. Red cell ABO incompatibility and production of tumour necrosis factor-alpha. Br J Haematol. 1991;78:540–4.CrossRefPubMed Davenport RD, Strieter RM, Kunkel SL. Red cell ABO incompatibility and production of tumour necrosis factor-alpha. Br J Haematol. 1991;78:540–4.CrossRefPubMed
9.
go back to reference Capon SM, Goldfinger D. Acute hemolytic transfusion reaction, a paradigm of the systemic inflammatory response: new insights into pathophysiology and treatment. Transfusion. 1995;35:513–20.CrossRefPubMed Capon SM, Goldfinger D. Acute hemolytic transfusion reaction, a paradigm of the systemic inflammatory response: new insights into pathophysiology and treatment. Transfusion. 1995;35:513–20.CrossRefPubMed
10.
go back to reference Simionatto CS, Cabal R, Jones RL, Galbraith RA. Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers. Am J Med. 1988;85:538–40.CrossRefPubMed Simionatto CS, Cabal R, Jones RL, Galbraith RA. Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers. Am J Med. 1988;85:538–40.CrossRefPubMed
11.
go back to reference Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–62.CrossRefPubMed Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–62.CrossRefPubMed
12.
go back to reference Tabibzadeh N, Estournet C, Placier S, Perez J, Bilbault H, Girshovich A, et al. Plasma heme-induced renal toxicity is related to a capillary rarefaction. Sci Rep. 2017;7:40156.CrossRefPubMedPubMedCentral Tabibzadeh N, Estournet C, Placier S, Perez J, Bilbault H, Girshovich A, et al. Plasma heme-induced renal toxicity is related to a capillary rarefaction. Sci Rep. 2017;7:40156.CrossRefPubMedPubMedCentral
13.
go back to reference Deuel JW, Schaer CA, Boretti FS, Opitz L, Garcia-Rubio I, Baek JH, et al. Hemoglobinuria-related acute kidney injury is driven by intrarenal oxidative reactions triggering a heme toxicity response. Cell Death Dis. 2016;7:e2064.CrossRefPubMedPubMedCentral Deuel JW, Schaer CA, Boretti FS, Opitz L, Garcia-Rubio I, Baek JH, et al. Hemoglobinuria-related acute kidney injury is driven by intrarenal oxidative reactions triggering a heme toxicity response. Cell Death Dis. 2016;7:e2064.CrossRefPubMedPubMedCentral
14.
go back to reference Lopas H, Birndorf NI, Robboy SJ. Experimental transfusion reactions and disseminated intravascular coagulation produced by incompatible plasma in monkeys. Transfusion. 1971;11:196–203.CrossRefPubMed Lopas H, Birndorf NI, Robboy SJ. Experimental transfusion reactions and disseminated intravascular coagulation produced by incompatible plasma in monkeys. Transfusion. 1971;11:196–203.CrossRefPubMed
15.
go back to reference Irani MS, Karafin MS, Ernster L. Red cell exchange to mitigate a delayed hemolytic transfusion reaction in a patient transfused with incompatible red blood cells. J Clin Apher. 2017;32:59–61.CrossRefPubMed Irani MS, Karafin MS, Ernster L. Red cell exchange to mitigate a delayed hemolytic transfusion reaction in a patient transfused with incompatible red blood cells. J Clin Apher. 2017;32:59–61.CrossRefPubMed
16.
go back to reference Weinstock C, Möhle R, Dorn C, Weisel K, Höchsmann B, Schrezenmeier H, et al. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion. Transfusion. 2015;55:605–10.CrossRefPubMed Weinstock C, Möhle R, Dorn C, Weisel K, Höchsmann B, Schrezenmeier H, et al. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion. Transfusion. 2015;55:605–10.CrossRefPubMed
17.
go back to reference Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. Kidney Int. 2016;90:974–84.CrossRefPubMed Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. Kidney Int. 2016;90:974–84.CrossRefPubMed
18.
go back to reference Duval CP, Alter HJ, Rath CE. Hemoglobin catabolism following a hemolytic transfusion reaction in a patient with sickle cell anemia. Transfusion. 1974;14:382–7.CrossRef Duval CP, Alter HJ, Rath CE. Hemoglobin catabolism following a hemolytic transfusion reaction in a patient with sickle cell anemia. Transfusion. 1974;14:382–7.CrossRef
Metadata
Title
A case of ABO-incompatible blood transfusion treated by plasma exchange therapy and continuous hemodiafiltration
Authors
Akio Namikawa
Yuko Shibuya
Haruki Ouchi
Hiroko Takahashi
Yoshitaka Furuto
Publication date
01-05-2018
Publisher
Springer Japan
Published in
CEN Case Reports / Issue 1/2018
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-018-0307-4

Other articles of this Issue 1/2018

CEN Case Reports 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.